SynthesisPLoS neglected tropical diseases2025
Burden of Shigella among children with diarrhea in the Americas: A systematic review and meta-analysis.
Synthesis in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of a NovelVaccines · 2026Article
- Berberine AlleviatesInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionShigella is a leading cause of diarrhea worldwide. While the burden of Shigella has been shown to be highest in Africa and Asia, recent studies have also shown considerable burden in the Americas. With several pediatric Shigella vaccines in clinical development, policymakers in the region will eventually consider whether a Shigella vaccine is appropriate for their setting.
methodsWe conducted a systematic review and meta-analyses to summarize the burden (characterized by prevalence, incidence, and attributable fraction estimates) of Shigella diarrhea among children under 72 months in the Americas, excluding the U.S., Canada, and Greenland. We searched published and pre-print articles available in six databases from January 1, 2000 through July 18, 2024. Random effects meta-analyses were conducted for subgroups of interest when relevant data from at least two studies were present.
resultsThis review included 34 studies conducted across 14 countries in the region. Prevalence was most frequently reported, followed by incidence, then attributable fraction. Across all prevalence studies that used a culture detection method (n = 23), the pooled prevalence of Shigella among diarrhea cases was 3.1% (95% CI: 1.6- 5.8). The pooled prevalence among 7 studies that used PCR/qPCR detection methods was 16.5% (95% CI: 11.1-24.0). Among culture-based results, the pooled prevalence estimate for children <12 months was 1.0% (95% CI: 0.1 - 7.7) compared to 4.6% (95% CI: 1.2 - 15.4) for children ≥12 months.
conclusionDespite varying reporting practices, we found Shigella to be an important contributor to diarrhea in many settings in the Americas with substantial heterogeneity. Limited geographic representation and variable reporting of age group specific estimates were the major gaps in data. Investment in Shigella surveillance in the Americas using a standardized methodology can contribute to accelerating Shigella vaccine development in consideration of regional preferences and optimal age of introduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.